Jim Beitel is currently leading corporate development and strategy for Avanir where his track record includes three "buy-side" transactions and the subsequent $3.5 billion acquisition of Avanir.  Jim has demonstrated his ability to deliver results for a variety of companies including early-stage venture-backed companies to large multi-national biopharmaceutical companies including Avanir, Amgen, Zacharon, and La Jolla Pharmaceutical Company.  His background includes complex license transactions and multi-billion dollar M&A deals with the ability to leverage strong experience in sales, marketing, and finance across multiple therapeutic areas.  Jim holds an MBA from Harvard and a degree in Engineering from the University of Kansas.